Back to search

Massachusetts Institute of Technology

Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer

Abstract

dc:description.abstract

Pretargeted radioimmunotherapy (PRIT) of cancer improves upon conventional radioimmunotherapy (RIT) by decoupling the pharmacokinetics of the targeting agent and the radioisotope. In order to improve upon PRIT, we have considered variables such as treatment setting and methodology, the transport and clearance characteristics of targeting agents, and the radionuclides used for therapy. PRIT has been modeled with the aim of examining the theoretical potential of PRIT under optimal conditions to kill every cell in malignant, avascular micrometastases. A mathematical model of PRIT was developed that combined a two-compartment pharmacokinetic model, antibody binding kinetics, diffusion and catabolism in tumor spheroids, and radiation dosimetry models for alpha- and beta-emitting radionuclides. This model demonstrated that it is theoretically possible to kill every cell in 100 tm radius micrometastases using 9Y- or 213Bi-based PRIT with acceptable toxicity as described. The therapeutic window for dosing radionuclide-carrying hapten was found to be strongly dependent on cell-specific parameters such as antigen concentration, void fraction, and the radiosensitivity parameter a, as well as on targeting agent molecular parameters such as the diffusivity and antigen-binding association rate.

Degree

thesis:*
Department dc:contributor.department
Massachusetts Institute of Technology. Dept. of Chemical Engineering.
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2007

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Zajic, Stefan C
Advisor dc:contributor.advisor
  • K. Dane Wittrup.

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Language dc:language.iso
eng

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1721.1/38971
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/38971

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
citation

Zajic, Stefan C. Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer. Massachusetts Institute of Technology, 2007. http://hdl.handle.net/1721.1/38971